Atrial Fibrillation

Atrial Fibrillation

Myocardial infarction joins the list of cardiovascular disorders associated with atrial fibrillation, and premature atrial contraction proves a variable that can assess that risk.

New research offers tips for doctors on better management of atrial fibrillation, and for patients on better self-management.

Andexanet alfa is a recombinant factor Xa molecule that binds to and sequesters factor Xa inhibitors in the blood, making them unavailable to bind to native factor Xa.

In new-onset atrial fibrillation there is good evidence for obtaining a troponin T level. High levels are associated with highest rates of stroke, embolism, and cardiac mortality.

Dabigatran was shown in post-hoc analysis of the RE-LY trial to be associated with an increased risk of MI compared with warfarin.

Rivaroxaban when used to treat patients with atrial fibrillation who have had a previous MI is associated with higher risk for adverse events.

Whether to prescribe an antiplatelet or antithrombotic agent for a patient who has AF but is otherwise healthy can be a difficult decision.


Subscribe to
Please Wait 20 seconds or click here to close